Exact Mass: 656.4291

Exact Mass Matches: 656.4291

Found 18 metabolites which its exact mass value is equals to given mass value 656.4291, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Enalkiren

3-amino-N-[(2S)-1-[[(2S)-1-[[(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-(4-methoxyphenyl)-1-oxopropan-2-yl]-3-methylbutanamide

C35H56N6O6 (656.4261)

C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors

Enalkiren

3-Amino-N-[1-({1-[(1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl)-C-hydroxycarbonimidoyl]-2-(1H-imidazol-5-yl)ethyl}-C-hydroxycarbonimidoyl)-2-(4-methoxyphenyl)ethyl]-3-methylbutanimidate

C35H56N6O6 (656.4261)

2-[[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-[(E)-undec-4-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C35H63NO8P+ (656.4291)

2-[[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-undecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C35H63NO8P+ (656.4291)

2-[[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-undecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C35H63NO8P+ (656.4291)

2-[hydroxy-[3-propanoyloxy-2-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C35H63NO8P+ (656.4291)

2-[hydroxy-[3-nonanoyloxy-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C35H63NO8P+ (656.4291)

2-[[3-heptanoyloxy-2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C35H63NO8P+ (656.4291)

2-[[2-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]oxy-3-pentanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C35H63NO8P+ (656.4291)

SLIGRL-NH2

C29H56N10O7 (656.4333)

SLIGRL-NH2 (Protease-Activated Receptor-2 Activating Peptide) is an agonist of Protease-Activated Receptor-2 (PAR-2)[1].

7-[20-(hexa-3,5-dien-1-yl)-12,21-dihydroxy-7,10,15,21-tetramethyl-4,9,14,19,25-pentaoxapentacyclo[13.10.0.0³,¹³.0⁵,¹⁰.0¹⁸,²⁴]pentacosan-8-yl]-3,4-dimethylhepta-2,4-dienal

C39H60O8 (656.4288)

(2e,4e)-7-[(1s,3r,5s,7s,8s,10r,12s,13s,15r,18s,20r,21r,24r)-20-[(3z)-hexa-3,5-dien-1-yl]-12,21-dihydroxy-7,10,15,21-tetramethyl-4,9,14,19,25-pentaoxapentacyclo[13.10.0.0³,¹³.0⁵,¹⁰.0¹⁸,²⁴]pentacosan-8-yl]-3,4-dimethylhepta-2,4-dienal

(2e,4e)-7-[(1s,3r,5s,7s,8s,10r,12s,13s,15r,18s,20r,21r,24r)-20-[(3z)-hexa-3,5-dien-1-yl]-12,21-dihydroxy-7,10,15,21-tetramethyl-4,9,14,19,25-pentaoxapentacyclo[13.10.0.0³,¹³.0⁵,¹⁰.0¹⁸,²⁴]pentacosan-8-yl]-3,4-dimethylhepta-2,4-dienal

C39H60O8 (656.4288)

6-{7-[(3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl)oxy]-11-methoxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-1-yl}-2-methyl-3-methylideneheptanoic acid

C39H60O8 (656.4288)

(2s,6r)-6-[(1r,3as,5ar,7r,9as,11s,11ar)-7-{[(3s)-3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl]oxy}-11-methoxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

(2s,6r)-6-[(1r,3as,5ar,7r,9as,11s,11ar)-7-{[(3s)-3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl]oxy}-11-methoxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

C39H60O8 (656.4288)